title: Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients.
abstract: This study was designed to confirm the appropriateness of the dose setting for a Japanese phase III study of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF), which had been based on model simulation employing phase II study data. The previously developed mixed-effects pharmacokinetic/pharmacodynamic (PK-PD) model, which consisted of an oral one-compartment model parameterized in terms of clearance, volume and a first-order absorption rate, was rebuilt and optimized using the data for 597 subjects from the Japanese phase III study, J-ROCKET AF. A mixed-effects modeling technique in NONMEM was used to quantify both unexplained inter-individual variability and inter-occasion variability, which are random effect parameters. The final PK and PK-PD models were evaluated to identify influential covariates. The empirical Bayes estimates of AUC and C(max) from the final PK model were consistent with the simulated results from the Japanese phase II study. There was no clear relationship between individual estimated exposures and safety-related events, and the estimated exposure levels were consistent with the global phase III data. Therefore, it was concluded that the dose selected for the phase III study with Japanese NVAF patients by means of model simulation employing phase II study data had been appropriate from the PK-PD perspective.
authors: Clinical Pharmacology Asia, Bayer Yakuhin Ltd., Osaka, Japan. masato.kaneko@bayer.com
authors: Masato
authors: M
authors: Kaneko
authors: Takahiko
authors: T
authors: Tanigawa
authors: Kensei
authors: K
authors: Hashizume
authors: Mariko
authors: M
authors: Kajikawa
authors: Masahiro
authors: M
authors: Tajiri
authors: Wolfgang
authors: W
authors: Mueck
mesh_terms: D044466:Asian People; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008954:Models, Biological; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban